检索结果-南通市图书馆

A cross-sectional study of post-COVID syndrome at a tertiary care center in Turkey

Asian Pacific Journal of Tropical Medicine 2022年第9期15卷 410-417页

作者： Efraim Guzel oya baydar toprak Burak Mete Yasemin Saygıdeger Bengu Curuk Sedat Kuleci Cukurova University Faculty of MedicineDepartment of Chest DiseasesAdanaTurkey Cukurova University Faculty of MedicineDepartment of Public HealthAdanaTurkey

Objective:To investigate long-term symptoms after acute COVID-19,the link between symptoms and respiratory function,radiological changes in the post-COVID period,and risk factors for post-COVID ***:In this cross-sectional study,123 participants who were admitted within the first 3 months were categorized as group 1,and those who applied after 3 months were categorized as group *** to thoracic imaging and pulmonary function tests,patients were split into 3 groups as mild,moderate and ***:At least one symptom was present in 91.9%and 61.8%in acute and post-COVID period,*** function tests were normal in 60(70.6%)in the first three months,and 30(78.9%)in 91-days to 1-year period after acute COVID-19 *** 3 months,22.4%of chest X-rays and 7.9%of computerized tomography revealed *** who developed acute complications(OR 9.91,95%CI 1.93-50.87),had 2 or more symptoms at admission(OR 7.73,95%CI 2.56-23.33),had 1%to 14%CT involvement(OR 3.05,95%CI 1.06-8.79),or had 50%or more CT involvement(OR 14.68,95%CI 1.24-172.55)had a higher risk of developing post-COVID ***:COVID-19 symptoms can last for long *** of symptoms,acute complications,and the extent of radiological involvement may all contribute to elevated risk of post-COVID *** a result,patients with COVID-19 should be checked for long-term clinical difficulties on regular basis.

关键词： Post-COVID syndrome COVID-19 Symptoms Pulmonary function tests Risk factors

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

SARS-CoV-2 infection rates after different vaccination schemes:An online survey in Turkey

引用

Asian Pacific Journal of Tropical Medicine 2022年第4期15卷 171-178页

作者： oya baydar toprak Sennur Ozen Berker Ozturk Burcu Ozturk Ebru Ozturk Mehmet Kitapci Nurdan Kokturk Chest Diseases Department Faculty of MedicineCukurova UniversityAdanaTurkey Department of Pulmonary Medicine Delta HospitalIstanbulTurkey Chest Diseases Department Aksaray Training and Research HospitalAksarayTurkey Department of Pulmonary Medicine Faculty of MedicineGazi UniversityAnkaraTurkey Department of Biostatistics Hacettepe UniversityAnkaraTurkey Department of Nuclear Medicine Integra Medical Imaging CenterAnkaraTurkey

Objective:To identify effects of various nationwide vaccination protocols on the evolution of new SARS-CoV-2 infections among adult population and to evaluate the safety of mRNA(BioNTech/Pfizer)***:Totally 10735 adult volunteers that received at least one dose of BioNTech/Pfizer or triple doses of CoronaVac participated in this cross-sectional-online survey between 1 and 10 September *** information was collected covering a 5-month period from April 2021 to September *** about people who were vaccinated with only single and double dose CoronaVac were not included in this ***:At least one side effect after single and double dose of BioNTech/Pfizer and triple doses of CoronaVac were observed in 42.1%,42.5%and 10.9%,*** most common side effects were shoulder/arm pain,weakness/fatigue,muscle/joint pain and *** side effects were the most frequent in single BioNTech/Pfizer,while it was the least in triple *** rate of positive PCR tests before vaccination was 17.6%,and decreased to 3.0%after *** rates of positive SARS CoV-2-PCR were 18.8%,3.5%,3.1%,0.5%and 4.6%in single BioNTech/Pfizer,double BioNTech/Pfizer,double CoronaVac+single BioNTech/Pfizer,double CoronaVac+double BioNTech/Pfizer and triple CoronaVac,*** 1.8%of PCR positive COVID-19 cases needed intensive unit care in the pre-vaccination period,intensive care unit was required in 0%,1.5%,2.4%,0%and 4.2%after single BioNTech/Pfizer,double BioNTech/Pfizer,double CoronaVac+single BioNTech/Pfizer,double CoronaVac+double BioNTech/Pfizer and triple CoronaVac,*** rate after vaccination was 0.4%.Conclusions:The rarity of COVID-19 infection after vaccination suggests that efficacy of vaccines is *** the other hand,the data underscore the critical importance of continued public health mitigation.

关键词： mRNA vaccine COVID-19 SARS-CoV-2 Vaccine schemes Reinfection Positivity rate after vaccination

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

The predictors of long-COVID in the cohort of Turkish Thoracic Society-TURCOVID multicenter registry:One year follow-up results

引用

Asian Pacific Journal of Tropical Medicine 2022年第9期15卷 400-409页

作者： Serap Argun Baris oya baydar toprak Pelin Duru Cetinkaya Fusun Fakili Nurdan Kokturk Seval Kul Ozgecan Kayalar Yildiz Tutuncu Emel Azak Mutlu Kuluozturk Pinar Aysert Yildiz Pelin Pinar Deniz Oguz Kilinc Ilknur Basyigit Hasim Boyaci Ismail Hanta Neslihan Kose Gulseren Sagcan Caglar Cuhadaroglu Hacer Kuzu Okur Hasan Selcuk Ozger Begum Ergan Mehtap Hafizoglu Abdullah Sayiner Esra Nurlu Temel Onder Ozturk Tansu Ulukavak Ciftci Ipek Kivilcim Oguzulgen Vildan Avkan Oguz Firat Bayraktar Ozlem Ataoglu Merve Ercelik Pinar Yildiz Gulhan Aysegul Tomruk Erdem Muge Meltem Tor oya Itil Hasan Bayram Department of Pulmonary Medicine Faculty of MedicineKocaeli UniversityKocaeliTurkey Department of Pulmonary Medicine Faculty of MedicineCukurova UniversityAdanaTurkey Department of Pulmonary Medicine University of Health SciencesAdana City Training and Research HospitalAdanaTurkey Department of Pulmonary Medicine Faculty of MedicineGaziantep UniversityGaziantepTurkey Department of Pulmonary Medicine Faculty of MedicineGazi UniversityAnkaraTurkey Department of Biostatistics Faculty of MedicineGaziantep UniversityGaziantepTurkey Koc University Research Center for Translational Medicine(KUTTAM) Koc University School of MedicineIstanbulTurkey Department of Immunology Koc University Research Center for Translational Medicine(KUTTAM)Koc University School of MedicineIstanbulTurkey Department of Infectious Disease and Clinical Microbiology Faculty of MedicineKocaeli UniversityKocaeli Turkey Department of Pulmonary Medicine Faculty of MedicineFirat UniversityElazigTurkey Department of Infectious Diseases and Clinical Microbiology Faculty of MedicineGazi UniversityAnkaraTurkey Department of Pulmonary Medicine Faculty of MedicineDokuz Eylul UniversityIzmirTurkey Department of Pulmonary Medicine Bilecik Training and Research HospitalBilecikTurkey Department of Pulmonary Medicine Altunizade Acibadem HospitalIstanbulTurkey Department of Pulmonary Medicine Faculty of MedicineEge UniversityIzmirTurkey Department of Infectious Diseases and Clinical Microbiology Faculty of MedicineSuleyman Demirel UniversityIspartaTurkey Department of Pulmonary Medicine Faculty of MedicineSuleyman Demirel UniversityIspartaTurkey Department of Infectious Disease and Clinical Microbiology Faculty of MedicineDokuz Eylul UniversityIzmirTurkey Department of Internal Medicine Faculty of MedicineDokuz Eylul UniversityIzmirTurkey Department of Pulmonary Medicine Faculty of MedicineDuzce UniversityDuzceTurkey Department of Pulmonary Medicine Faculty of MedicineZonguldak Bulent Ecevit UniversityZongu

Objective:To evaluate long-term effects of COVID-19,and to determine the risk factors in long-COVID in a cohort of the Turkish Thoracic Society(TTS)-TURCOVID multicenter ***:Thirteen centers participated with 831 patients;504 patients were enrolled after *** study was designed in three-steps:(1)Phone questionnaire;(2)retrospective evaluation of the medical records;(3)face-to-face ***:In the first step,93.5%of the patients were hospitalized;61.7%had a history of pneumonia at the time of diagnosis.A total of 27.1%reported clinical symptoms at the end of the first ***(17.00%),fatigue(6.30%),and weakness(5.00%)were the most prevalent long-term *** incidence of long-term symptoms was increased by 2.91 fold(95%CI 1.04-8.13,P=0.041)in the presence of chronic obstructive pulmonary disease and by 1.84 fold(95%CI 1.10-3.10,P=0.021)in the presence of pneumonia at initial diagnosis,3.92 fold(95%CI 2.29-6.72,P=0.001)of dyspnea and 1.69 fold(95%CI 1.02-2.80,P=0.040)fatigue persists in the early-post-treatment period and 2.88 fold(95%CI 1.52-5.46,P=0.001)in the presence of emergency service admission in the post COVID *** step 2,retrospective analysis of 231 patients revealed that 1.4%of the chest X-rays had not significantly improved at the end of the first year,while computed tomography(CT)scan detected fibrosis in 3.4%.In step 3,138(27.4%)patients admitted to face-to-face visit at the end of first year;at least one symptom persisted in 49.27%*** most common symptoms were dyspnea(27.60%),psychiatric symptoms(18.10%),and fatigue(17.40%).Thorax CT revealed fibrosis in 2.4%***:COVID-19 symptoms can last for extended lengths of time,and severity of the disease as well as the presence of comorbidities might contribute to increased ***-term clinical issues should be regularly evaluated after COVID-19.

关键词： Long COVID-19 Dyspnea Fatigue Comorbidity

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：